Status:
UNKNOWN
Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD
Lead Sponsor:
Yonsei University
Conditions:
Non-alcoholic Fatty Liver Disease
Type 2 Diabetes
Eligibility:
All Genders
20-80 years
Brief Summary
To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia. To examine the association or effects of clinical and ...
Eligibility Criteria
Inclusion
- dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum LDL-C≥100mg/dl, or taking medication to lower LDL-C levels (e.g. statin, ezetimibe, etc.)
- type 2 diabetes 1. defined according to the ADA guideline (DM definition) or 2. taking any anti-diabetic medications
- non-alcoholic fatty liver disease (NAFLD) 1. diagnosed as having fatty liver by ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram (Fibroscan) or 3. diagnosed as having fatty liver by abdomina CT scan
- Normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. BMI \<25kg/m2
Exclusion
- subjects who refused to agree with informed consents
- subjects with organ-transplantation
- serum creatinine ≥1.5mg/dl
- pregnant women
- liver cancer or pancreatic cancer
- subjects with chronic hepatitis B or C virus infection
- for NAFLD group, subjects with excessive alcohol consumption (men: ≥210g of alcohol per week, women: ≥140g of alcohol per week)
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02285218
Start Date
April 1 2014
End Date
March 1 2019
Last Update
March 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea, 120-752